Publications by authors named "Kay Seden"

Claim this Profile
C
Clinical, pharmacological, and qualitative characterization of drug-drug interactions in pregnant women initiating HIV therapy in Sub-Saharan Africa.
Daniel Kiiza, Danial Rostami-Hochaghan, Yussif Alhassan, Kay Seden, Helen Reynolds

J Antimicrob Chemother· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
7
72 weeks post-partum follow-up of dolutegravir versus efavirenz initiated in late pregnancy (DolPHIN-2): an open-label, randomised controlled study.
Thokozile R Malaba, Irene Nakatudde, Kenneth Kintu, Angela Colbers, Tao Chen, Kay Seden

Lancet HIV· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patient experiences of switching from Efavirenz- to Dolutegravir-based antiretroviral therapy: a qualitative study in Uganda.
Adelline Twimukye, Miriam Laker, Eva Agnes Laker Odongpiny, Florence Ajok, Henry Onen, Kay Seden

BMC Infect Dis· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Potential Teratogenicity Alert for Women Conceiving on Dolutegravir-Based Regimens: An Assessment of Risk Communication by an Urban HIV Clinic in Uganda and Choices made by Women.
Eva Agnes Odongpiny Laker, Arnold Arinaitwe, Noela Owarwo, Annet Onzia, Benson Nasasira, Kay Seden

Drug Saf· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dolutegravir versus efavirenz in women starting HIV therapy in late pregnancy (DolPHIN-2): an open-label, randomised controlled trial.
Kenneth Kintu, Thokozile R Malaba, Jesca Nakibuka, Christiana Papamichael, Angela Colbers, Kay Seden

Lancet HIV· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
British HIV Association guidelines for the management of tuberculosis in adults living with HIV 2019.
Margherita Bracchi, Clare van Halsema, Frank Post, Funmi Awosusi, Alison Barbour, Kay Seden

HIV Med· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High prevalence and long duration of nervous system and psychiatric adverse drug reactions in Ugandan patients taking efavirenz 600 mg daily.
Kay Seden, Daniel Kiiza, Eva Laker, Walter J Arinaitwe, Catriona Waitt

J Antimicrob Chemother· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of an evidence evaluation and synthesis system for drug-drug interactions, and its application to a systematic review of HIV and malaria co-infection.
Kay Seden, Sara Gibbons, Catia Marzolini, Jonathan M Schapiro, David M Burger

PLoS One· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Drug interactions and the role of pharmacokinetic trials in guiding choices in first-line HIV therapy in low-income and middle-income countries.
Kay Seden, Marta Boffito, Saye Khoo

Curr Opin HIV AIDS· July 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Use of a physiologically-based pharmacokinetic model to simulate artemether dose adjustment for overcoming the drug-drug interaction with efavirenz.
Marco Siccardi, Adeniyi Olagunju, Kay Seden, Farid Ebrahimjee, Steve Rannard

In Silico Pharmacol· December 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prediction of drug-drug interactions between various antidepressants and efavirenz or boosted protease inhibitors using a physiologically based pharmacokinetic modelling approach.
Marco Siccardi, Catia Marzolini, Kay Seden, Lisa Almond, Anna Kirov

Clin Pharmacokinet· July 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Drug-drug interactions between antiretrovirals and drugs used in the management of neglected tropical diseases: important considerations in the WHO 2020 Roadmap and London Declaration on Neglected Tropical Diseases.
Kay Seden, Saye Khoo, David Back, Natalie Prevatt, Mohammed Lamorde

AIDS· March 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Global patient safety and antiretroviral drug-drug interactions in the resource-limited setting.
Kay Seden, Saye H Khoo, David Back, Pauline Byakika-Kibwika, Mohammed Lamorde

J Antimicrob Chemother· January 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cross-sectional study of prescribing errors in patients admitted to nine hospitals across North West England.
Kay Seden, Jamie J Kirkham, Tom Kennedy, Michael Lloyd, Sally James

BMJ Open· January 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Directly acting antivirals for hepatitis C and antiretrovirals: potential for drug-drug interactions.
Kay Seden, David Back

Curr Opin HIV AIDS· November 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prevalence of potential drug-drug interactions involving antiretroviral drugs in a large Kenyan cohort.
Gabriel Kigen, Sylvester Kimaiyo, Winstone Nyandiko, Brian Faragher, Edwin Sang, Kay Seden

PLoS One· February 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Grapefruit-drug interactions.
Kay Seden, Laura Dickinson, Saye Khoo, David Back

Drugs· December 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
New directly acting antivirals for hepatitis C: potential for interaction with antiretrovirals.
Kay Seden, David Back, Saye Khoo

J Antimicrob Chemother· June 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antiretroviral drug interactions: often unrecognized, frequently unavoidable, sometimes unmanageable.
Kay Seden, David Back, Saye Khoo

J Antimicrob Chemother· July 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis